PO.CL01.15 · 临床研究

解码口腔癌进展的多组学特征

Decoding the multiomic signatures of oral cancer progression

海报缩略图:解码口腔癌进展的多组学特征
编号 1190 展板 14 时间 4/19 02:00–05:00 区域 Section 46 主讲 Maple (Xiao) Lei, BS
分会场 Prognostic Biomarkers 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Maple Lei1, Kelly Yi Ping Liu2, Steven John Jones3, Catherine FY Poh4

1Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada,2University of British Columbia, Vancouver, BC, Canada,3BC Cancer Agency, Vancouver, BC, Canada,4Associate Professor, University of British Columbia Faculty of Dentistry, Vancouver, BC, Canada

摘要 Abstract

中文摘要
口腔鳞状细胞癌(OCSCC)常先于口腔上皮异型增生(OED)发生,然而当前临床工具识别哪些口腔潜在恶性病变(OPML)将进展的能力有限。本研究采用整合多组学方法识别进展的分子特征,并定义可能改善风险评估的生物标志物。 我们分析了在手术时采集的注释完善的速冻口腔组织,同时采集血液样本获取种系DNA。组织样本经病理复核并显微切割,标记为“癌前”或“恶性”。采用短读长全基因组测序(肿瘤≥80×,种系≥30×)和RNA测序(每文库≥2亿reads)表征体细胞突变、拷贝数改变和转录差异。部分样本接受长读长nanopore测序(20×覆盖度)以细化甲基化模式及其与表达的关系。数据采用成熟的流程整合,候选特征通过基于机器学习的分类进行评估。使用AI增强摘要的清晰度。 共提交305份患者样本,其中96%(138例OED,154例OSCC)成功测序。癌前和恶性组的突变图谱相似,共有TP53、CDKN2A、FAT1、NOTCH1和CASP8的改变。HLA-A成为差异突变最显著的基因,指向免疫相关通路的改变。差异表达分析显示样本类型的清晰分离,OSCC中表达广泛增加。使用来自961个基因的TPM值,在迭代特征消除后训练了一个概念验证随机森林分类器,得到一个置信度92%、AUC 96%的模型。信息量最大的特征与差异表达最显著的基因一致,通路分析提示在信号传导、黏附和结构组织方面的富集。差异甲基化分析(75例OED,40例OSCC)显示OSCC样本中CpG岛甲基化更高。差异甲基化最显著的基因包括参与细胞周期调控和信号传导的ARHGEF17和PHLDB1,以及此前在口腔上皮模型中被描述为细胞生长和运动调节因子的MIR27B。 本研究采用迄今最大、最全面分析的OED队列之一,表明病变在恶性转化前即存在可检测的不同基因组、表观基因组和转录变化。所识别的趋同关键标志物支持开发和验证可临床应用的检测,用于福尔马林固定石蜡包埋样本以早期识别高风险病变。正在进行的工作将这些分子特征与纵向临床结局整合,并将其映射到生物学通路和口腔癌分子亚型,以推进筛查、早期干预和个体化患者管理。
查看英文原文 English abstract
Oral cavity squamous cell carcinoma (OCSCC) is frequently preceded by oral epithelial dysplasias (OEDs), yet current clinical tools provide limited ability to identify which OPMLs will progress. This study applied an integrated multiomics approach to identify molecular features of progression and define biomarkers that may improve risk assessment. We analyzed well-annotated flash-frozen oral tissues collected at surgery, with concurrent blood samples for germline DNA. Tissue samples were pathologically reviewed and microdissected to be labelled as “premalignant” or “malignant”. Short-read whole-genome sequencing (≥80× tumor, ≥30× germline) and RNA sequencing (≥200 million reads per library) were used to characterize somatic mutations, copy number alterations, and transcriptional differences. A subset of samples underwent long-read nanopore sequencing (20× coverage) to refine methylation patterns and their relationship to expression. Data were integrated using established pipelines, and candidate features were evaluated through machine learning-based classification. AI was used to enhance abstract clarity. A total of 305 patient samples were submitted of which 96% (138 OED, 154 OSCC) were successfully sequenced. Mutational landscapes were similar across premalignant and malignant groups, sharing alterations in TP53 , CDKN2A , FAT1 , NOTCH1 , and CASP8 . HLA-A emerged as the top differentially mutated gene, pointing to altered immune-related pathways. Differential expression analysis showed clear separation of sample types, with broad increases in expression in OSCC. TPM values from 961 genes were used to train a proof-of-concept random forest classifier after iterative feature elimination, yielding a model with 92% confidence and 96% AUC. The most informative features aligned with top differentially expressed genes, and pathway analysis indicated enrichment in signaling, adhesion, and structural organization. Differential methylation analysis (75 OED, 40 OSCC) showed higher CpG island methylation in OSCC samples. Top differentially methylated genes included ARHGEF17 and PHLDB1 , which participate in cell cycle regulation and signaling, and MIR27B , previously described as a regulator of cellular growth and movement in oral epithelial models. Using one of the largest, most comprehensively profiled OED cohorts to date, this work shows that lesions harbor distinct genomic, epigenomic, and transcriptional changes detectable before malignant transformation. Convergent key markers identified support development and validation of clinically actionable tests to be applied to formalin-fixed paraffin embedded samples for early identification of higher-risk lesions. Ongoing efforts integrate these molecular signatures with longitudinal clinical outcomes and map them to biological pathways and molecular oral cancer subtypes to advance screening, early intervention, and individualized patient management.
利益披露 Disclosure
M. Lei, None.

← 返回 AACR 2026 检索